Prolia and XGEVA
Q2 2026 Prolia sales fell 32% to $759 million and XGEVA fell 34% to $352 million as biosimilars take share.
The numbers
What it is
Denosumab medicines for osteoporosis (Prolia) and for preventing skeletal events in cancer patients (XGEVA). Amgen's largest product group by 2025 sales, now losing volume and price to biosimilars.
Why it matters to the stock. Prolia and XGEVA are the biggest source of revenue decline. Each quarter's volume and net price shows how fast biosimilars are taking share.
News
Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS
Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08.
Amgen Q1 2026 revenue rises 6% to $8.6 billion; full-year guidance lifted
Amgen reported first-quarter 2026 total revenue of $8.6 billion, up 6%, and non-GAAP EPS of $5.15 against $4.90 a year earlier.